Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARCOT study of single-dose denosumab in acute Charcot foot
NL-OMON21814Recruiting
- Sponsor
- AMC Health
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of denosumab in Charcot neuroarthropathy (CN) and diabetes mellitus (DM) (2 arms), sponsored by AMC Health. Primary endpoint: Time to cessation of total contact cast with radiological bone quality improvement. Started Mar 2017; status: recruiting.
02
Drugs
denosumab
03
Conditions
Charcot neuroarthropathy (CN)diabetes mellitus (DM)
Beyond the preview
Go deeper on NL-OMON21814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21814.